Serina Therapeutics, Inc.

SER Healthcare Biotechnology

In the quarter to June 2026, revenue grew 2,500.0%, EPS grew 16.7% and free cash flow fell 76.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.77 0.02 −1.12%
Market cap
$45.5M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
2/9
Altman Z
−22.07
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.65 4.18 1.71 1.31
Net Debt/EBITDA
2.98 3.47 0.02 0.90
Debt/Equity
0.16 0.17 (79.62) 1.81
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.41) (0.38) (0.59) (0.37)
Book value per Share
1.14 1.46 0.00 0.15
Free Cash Flow
(6.71) (4.59) (6.03) (3.86)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates